Response to: 'Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease' by Campochiaro et al.
Fleur Cohen-AubartNeila BenameurZahir AmouraJulien HarochePublished in: Annals of the rheumatic diseases (2020)